BioShin Limited Broadens Senior Leadership Team with Veteran Pharma and Biotech Strategy and Business Development Executive
April 19, 2021 07:30 ET
|
BioShin
SHANGHAI, China, April 19, 2021 (GLOBE NEWSWIRE) -- BioShin Limited, biopharmaceutical company focused on the discovery, development and commercialization of novel, life-improving treatments for...
BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine.
November 22, 2020 21:32 ET
|
BioShin
SHANGHAI, China, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BioShin Limited announced today that the first patients were enrolled in its regional multi-center study, BHV3000-310, being conducted in China and...
标新 rimegepant (BHV-3000) 偏头痛急性期治疗的亚太多中心III期临床研究完成首例受试者入组
November 22, 2020 20:00 ET
|
BioShin
上海, Nov. 23, 2020 (GLOBE NEWSWIRE) -- 总部位于中国上海的临床阶段生物制药企业标新（BioShin...
Biohaven 亚太区子公司标新获 6000万美元 A 轮融资以在亚太地区推进其神经科学产品管线
September 28, 2020 07:00 ET
|
BioShin
于 2020年第四季度在中韩两国启动用于偏头痛急性治疗的 NURTEC ODT 三期研究及在国内启动用于脊髓小脑共济失调治疗的 Troriluzole 注册研究 任命 Donnie McGrath 担任标新总裁兼执行主席；任命 Karl Lintel 担任标新首席执行官；任命来自 Biohaven 的 Vlad Coric 和 Donnie McGrath 以及来自奥博资本 (OrbiMed)...